Royalty Pharma plc Contracts & Agreements

58 Contracts & Agreements
Browse by Contract Category
Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Membership Interests Purchase Agreement, dated January 10, 2025, among Royalty Pharma, LLC, RP Management, LLC, the Sellers named therein and Royalty Pharma Holdings Ltd
Purchase Agreements
Royalty Pharma plc
Pharmaceuticals
2025
Exchange Agreement dated December 31, 2024, among the Company, RP Holdings, RPI US Partners 2019, LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP, RPI...
Exchange Agreements
Royalty Pharma plc
Pharmaceuticals
2024
Third Supplemental Indenture, dated as of June 10, 2024, among Royalty Pharma plc, Royalty Pharma Holdings Ltd and Wilmington Trust, National Association, as Trustee
Indenture Agreements
Royalty Pharma plc
2024
Underwriting Agreement, dated as of June 3, 2024, by and among Royalty Pharma plc, Royalty Pharma Holdings Ltd, RP Management, LLC and the underwriters named therein
Underwriting Agreements
Royalty Pharma plc
2024
Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934
Royalty Pharma plc
2024
Amended and Restated Revolving Credit Agreement, dated as of September 15, 2021, as amended by Amendment No. 1, dated as of October 31, 2022, as amended by Amendment No. 2, dated...
Credit Agreements
Royalty Pharma plc
2023
Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934
Royalty Pharma plc
Pharmaceuticals
2023
Second Amended and Restated Management and Services Agreement dated October 3, 2022, among Royalty Pharma Investments 2019 ICAV and RP Management, LLC
Management Agreements
Royalty Pharma plc
Pharmaceuticals
DE
2022
Amended and Restated Management and Services Agreement dated October 3, 2022, among Royalty Pharma Holdings Limited and RP Management, LLC
Management Agreements
Royalty Pharma plc
2022
Amended and Restated Management and Services Agreement dated October 3, 2022, among the Company and RP Management, LLC
Management Agreements
Royalty Pharma plc
2022
Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934
Royalty Pharma plc
2022
Second Supplemental Indenture, dated as of July 26, 2021, Royalty Pharma plc, Royalty Pharma Holdings Ltd. and Wilmington Trust, National Association, as Trustee
Indenture Agreements
Royalty Pharma plc
Pharmaceuticals
NY
2021
Underwriting Agreement, dated as of July 15, 2021 by and among Royalty Pharma plc, Royalty Pharma Holdings Limited, RP Management, LLC and the underwriters named therein
Underwriting Agreements
Royalty Pharma plc
Pharmaceuticals
NY
2021
Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934
Royalty Pharma plc
2021
Amendment No. 2 to the Amended and Restated Purchase and Sale Agreement, dated October 30, 2020, by and among RPI Finance Trust, RPI 2019 Intermediate Finance Trust and Cystic...
Purchase Agreements
Royalty Pharma plc
2020
Form of Deed of Indemnity
Royalty Pharma plc
2020
Registration Rights Agreement, dated as of September 2, 2020, among Royalty Pharma plc, Royalty Pharma Holdings Ltd, BofA Securities, Inc., Citigroup Global Markets Inc., Goldman...
Registration Rights Agreements
Royalty Pharma plc
Pharmaceuticals
NY
2020
First Supplemental Indenture, dated as of September 2, 2020, among Royalty Pharma plc, Royalty Pharma Holdings Ltd. and Wilmington Trust, National Association, as Trustee
Indenture Agreements
Royalty Pharma plc
2020
Indenture, dated as of September 2, 2020, among Royalty Pharma plc, Royalty Pharma Holdings Ltd and Wilmington Trust, National Association, as Trustee
Indenture Agreements
Royalty Pharma plc
2020
Form of Independent Director Equity Incentive Plan
Bonus & Incentive Agreements
Royalty Pharma plc
Pharmaceuticals
2020
Amended and Restated Management and Services Agreement dated June 11, 2020, among Royalty Pharma Investments 2019 ICAV and RP Management, LLC
Management Agreements
Royalty Pharma plc
Pharmaceuticals
DE
2020
Amendment No. 7 to Research, Development and Commercialization Agreement, dated September 1, 2016, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis...
Development Agreements
Royalty Pharma plc
Pharmaceuticals
2020
Amendment No. 5 to Research, Development and Commercialization Agreement, dated April 1, 2011, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation...
Development Agreements
Royalty Pharma plc
2020
Amendment No. 2 to Research, Development and Commercialization Agreement, dated January 1, 2006, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation...
Development Agreements
Royalty Pharma plc
Pharmaceuticals
2020
Amendment No. 1 to Research, Development and Commercialization Agreement, dated January 6, 2006 by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation...
Development Agreements
Royalty Pharma plc
Pharmaceuticals
2020
Research, Development and Commercialization Agreement, dated May 24, 2004, between the Cystic Fibrosis Foundation Therapeutics Incorporated and Vertex Pharmaceuticals Inc., as...
Development Agreements
Royalty Pharma plc
2020
Amendment No. 1 to the Amended and Restated Purchase and Sale Agreement, dated October 13, 2016 with the Cystic Fibrosis Foundation
Purchase Agreements
Royalty Pharma plc
Pharmaceuticals
2020
Amended and Restated Purchase and Sale Agreement, dated November 14, 2014, with the Cystic Fibrosis Foundation Therapeutics Incorporated
Purchase Agreements
Royalty Pharma plc
Pharmaceuticals
DE
2020
Director Appointment Agreement, dated June 9, 2020, between the Company and Mr. Germano Giuliani
Royalty Pharma plc
Pharmaceuticals
2020
Registration Rights Agreement dated June 18, 2020, among the Company and the Persons listed on Schedule A and Schedule B thereto
Registration Rights Agreements
Royalty Pharma plc
2020
Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Ltd, RPI US Partners 2019, LP, RPI International Holdings 2019, LP, RPI International Partners...
Exchange Agreements
Royalty Pharma plc
2020
Management and Services Agreement dated June 15, 2020, among the Company and RP Management, LLC
Management Agreements
Royalty Pharma plc
Pharmaceuticals
NY
2020
Form of Class A Ordinary Share Certificate
Share Agreements
Royalty Pharma plc
Pharmaceuticals
2020
Form of Underwriting Agreement
Underwriting Agreements
Royalty Pharma plc
2020
Registration Rights Agreement, dated as of September 2, 2020, among Royalty Pharma plc, Royalty Pharma Holdings Ltd., BofA Securities, Inc., Citigroup Global Markets Inc., Goldman...
Registration Rights Agreements
Royalty Pharma plc
Pharmaceuticals
NY
2020
First Supplemental Indenture, dated as of September 2, 2020, among Royalty Pharma plc, Royalty Pharma Holdings Ltd. and Wilmington Trust, National Association, as Trustee
Indenture Agreements
Royalty Pharma plc
2020
Indenture, dated as of September 2, 2020, among Royalty Pharma plc, Royalty Pharma Holdings Ltd. and Wilmington Trust, National Association, as Trustee
Indenture Agreements
Royalty Pharma plc
2020
Registration Rights Agreement dated June 18, 2020, among the Company and the Persons listed on Schedule A and Schedule B thereto
Registration Rights Agreements
Royalty Pharma plc
Pharmaceuticals
NY
2020
Amended and Restated Management and Services Agreement dated June 11, 2020, among Royalty Pharma Investments 2019 ICAV and RP Management, LLC
Management Agreements
Royalty Pharma plc
2020
Management and Services Agreement dated June 15, 2020, among the Company and RP Management, LLC
Management Agreements
Royalty Pharma plc
2020
Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI International Holdings 2019, LP, RPI International...
Exchange Agreements
Royalty Pharma plc
2020
Director Appointment Agreement, dated June 9, 2020, between the Company and Mr. Germano Giuliani
Royalty Pharma plc
Pharmaceuticals
2020
Form of Class A Ordinary Share Certificate
Share Agreements
Royalty Pharma plc
2020
Form of Independent Director Equity Incentive Plan
Bonus & Incentive Agreements
Royalty Pharma plc
Pharmaceuticals
2020
Form of Underwriting Agreement
Underwriting Agreements
Royalty Pharma plc
Pharmaceuticals
NY
2020
Amendment No. 1 to the Amended and Restated Purchase and Sale Agreement, dated October 13, 2016 with the Cystic Fibrosis Foundation
Purchase Agreements
Royalty Pharma plc
Pharmaceuticals
2020
Amended and Restated Purchase and Sale Agreement, dated November 14, 2014, with the Cystic Fibrosis Foundation Therapeutics Incorporated
Purchase Agreements
Royalty Pharma plc
Pharmaceuticals
DE
2020
Form of Deed of Indemnity
Royalty Pharma plc
2020
Form of Registration Rights Agreement
Registration Rights Agreements
Royalty Pharma plc
2020
Form of Exchange Agreement
Exchange Agreements
Royalty Pharma plc
Pharmaceuticals
DE
2020
Form of Management and Services Agreement, dated , 2020, among Royalty Pharma plc and RP Management, LLC
Management Agreements
Royalty Pharma plc
Pharmaceuticals
NY
2020
Form of Amended and Restated Management and Services Agreement, dated, 2020, among Royalty Pharma Investments 2019 ICAV and RP Management, LLC
Management Agreements
Royalty Pharma plc
2020
Amendment No. 7 to Research, Development and Commercialization Agreement, dated September 1, 2016, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis...
Development Agreements
Royalty Pharma plc
Pharmaceuticals
2020
Amendment No. 5 to Research, Development and Commercialization Agreement, dated April 1, 2011, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation...
Development Agreements
Royalty Pharma plc
2020
Amendment No. 2 to Research, Development and Commercialization Agreement, dated January 1, 2006, by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation...
Development Agreements
Royalty Pharma plc
Pharmaceuticals
2020
Amendment No. 1 to Research, Development and Commercialization Agreement, dated January 6, 2006 by and between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation...
Development Agreements
Royalty Pharma plc
Pharmaceuticals
2020
Research, Development and Commercialization Agreement, dated May 24, 2004, between the Cystic Fibrosis Foundation Therapeutics Incorporated and Vertex Pharmaceuticals Inc., as...
Development Agreements
Royalty Pharma plc
2020
Credit Agreement, dated February 11, 2020, between RPI 2019 Intermediate Finance Trust, as borrower, Bank of America, N.A., as administrative agent, and certain lender parties...
Credit Agreements
Royalty Pharma plc
2020